Trexquant Investment LP Boosts Stock Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Trexquant Investment LP raised its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 50.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 151,083 shares of the biopharmaceutical company's stock after purchasing an additional 50,826 shares during the period. Trexquant Investment LP owned approximately 0.31% of Theravance Biopharma worth $1,422,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in TBPH. Geode Capital Management LLC boosted its position in shares of Theravance Biopharma by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 862,802 shares of the biopharmaceutical company's stock valued at $8,121,000 after buying an additional 4,823 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Theravance Biopharma by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 293,936 shares of the biopharmaceutical company's stock valued at $2,766,000 after acquiring an additional 2,060 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Theravance Biopharma by 2.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 266,879 shares of the biopharmaceutical company's stock worth $2,151,000 after acquiring an additional 7,620 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Theravance Biopharma by 3.7% in the 4th quarter. Wellington Management Group LLP now owns 198,491 shares of the biopharmaceutical company's stock worth $1,868,000 after acquiring an additional 7,162 shares in the last quarter. Finally, Jane Street Group LLC raised its holdings in shares of Theravance Biopharma by 1.1% in the third quarter. Jane Street Group LLC now owns 144,575 shares of the biopharmaceutical company's stock valued at $1,165,000 after purchasing an additional 1,640 shares during the last quarter. 99.10% of the stock is owned by institutional investors.

Remove Ads

Theravance Biopharma Price Performance

Shares of Theravance Biopharma stock traded down $0.13 during trading hours on Tuesday, hitting $8.60. 48,794 shares of the company's stock traded hands, compared to its average volume of 285,567. The stock has a market capitalization of $425.45 million, a price-to-earnings ratio of -8.51 and a beta of 0.14. Theravance Biopharma, Inc. has a 12-month low of $7.44 and a 12-month high of $10.90. The company has a fifty day simple moving average of $9.16 and a 200-day simple moving average of $9.14.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.26). The company had revenue of $18.75 million for the quarter, compared to analysts' expectations of $29.90 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. On average, analysts forecast that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a "buy" rating and set a $15.00 price target on shares of Theravance Biopharma in a report on Tuesday, February 25th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $11.33.

Insider Buying and Selling

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the firm's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 309,565 shares of the company's stock, valued at $2,786,085. This trade represents a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 6.90% of the stock is currently owned by insiders.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.